hero section gradient
15 handpicked stocks

China's Manufacturing Rebound

Early signs of recovery in China's manufacturing sector are creating investment opportunities. This collection features carefully selected companies positioned to benefit as the world's largest manufacturing economy starts to stabilize and grow again.

Author avatar

Han Tan | Market Analyst

Published on June 30

Your Basket's Financial Footprint

Aggregate market capitalisation and breakdown for the 'China's Manufacturing Rebound' basket.

Key Takeaways for Investors:
  • Large-cap dominance generally implies lower volatility and closer tracking to broad market performance.
  • Suitable as a core holding for diversified portfolios, rather than a speculative, high-growth position.
  • Expect steady, long-term value creation; short-term explosive gains are less likely from large-cap concentration.
Total Market Cap
  • BHP: $143.35B

  • RIO: $116.84B

  • VALE: $51.22B

  • Other

About This Group of Stocks

1

Our Expert Thinking

China's manufacturing PMI has risen for two consecutive months, signaling a potential turnaround. Companies in this group operate across the industrial value chain and stand to directly benefit from increased factory output and demand in the world's largest manufacturing economy.

2

What You Need to Know

This collection represents a tactical opportunity tied to economic recovery. It includes diverse companies from miners supplying raw materials to manufacturers of machinery and automation systems. Any improvement in Chinese industrial activity creates ripple effects benefiting these firms.

3

Why These Stocks

These companies were specifically selected for their direct exposure to China's manufacturing sector. Each business plays a critical role in the industrial supply chain, from providing essential raw materials to delivering the equipment and technology needed for production growth.

Why You'll Want to Watch These Stocks

🔄

Early Signs of Recovery

China's manufacturing PMI has risen for two consecutive months, signaling a potential turnaround that early investors could capitalize on before the broader market catches up.

🌐

Global Ripple Effects

When China's factories accelerate production, it triggers demand across the entire industrial supply chain, creating a wave of opportunity from raw materials to finished goods.

📊

Cyclical Opportunity Moment

Industrial recoveries like this often follow predictable patterns, potentially rewarding investors who recognize the early indicators and position themselves accordingly.

Get the full story on this Basket. Read our detailed article on its risks and potential.

Read Full Insight

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

Global Infrastructure Partners: UAE Exposure Risks

Global Infrastructure Partners: UAE Exposure Risks

The UAE's strategic push for economic diversification and smart city development is creating significant demand for advanced construction and infrastructure solutions. This basket provides exposure to a selection of US and EU-listed companies that supply essential materials, technology, and engineering services to the region's projects.

UAE Infrastructure Global Suppliers Breakdown

UAE Infrastructure Global Suppliers Breakdown

As the UAE continues its ambitious economic diversification, demand for world-class infrastructure creates opportunities for the companies that build it. This basket offers exposure to US and EU-listed industrial, materials, and technology firms that are integral to developing these large-scale projects.

Antiviral M&A Wave: Biotech Opportunities in 2025

Antiviral M&A Wave: Biotech Opportunities in 2025

Merck's $9.2 billion acquisition of Cidara Therapeutics strengthens its antiviral pipeline as a key patent nears expiry. This major deal signals a growing trend of pharmaceutical giants buying smaller biotechs, creating potential opportunities among companies with promising infectious disease therapies.

Frequently Asked Questions